2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
Reversal agents for current and forthcoming direct oral anticoagulants
Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
[HTML][HTML] Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes
SFB van der Horst, ESL Martens, PL den Exter… - Thrombosis research, 2023 - Elsevier
Background Idarucizumab has been approved to reverse the anticoagulant effect of
dabigatran. However, there is little knowledge of the effectiveness and safety of …
dabigatran. However, there is little knowledge of the effectiveness and safety of …
[HTML][HTML] An update on the reversal of non-vitamin K antagonist oral anticoagulants
Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran
and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban …
and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban …
[HTML][HTML] Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting
Background: Idarucizumab has been included in guidelines for the management of bleeding
or surgical procedure in dabigatran-treated patients without need for biological monitoring …
or surgical procedure in dabigatran-treated patients without need for biological monitoring …
Effectiveness and safety of dabigatran reversal with idarucizumab in the Taiwanese population: A comparison based on eligibility for inclusion in clinical trials
JW Dai, CH Wang, CL Chu, SC Liao - Medicina, 2023 - mdpi.com
Background and Objectives: The effectiveness and safety of idarucizumab for the reversal of
the effects of dabigatran have been proven. However, there remains a paucity of literature …
the effects of dabigatran have been proven. However, there remains a paucity of literature …
[HTML][HTML] Real-world experience with reversal of dabigatran by idarucizumab
SB Haastrup, M Hellfritzsch, M Nybo, AM Hvas… - Thrombosis …, 2021 - Elsevier
Aims Idarucizumab reverses the anticoagulant effect of dabigatran. We aimed to investigate
real-world experience with idarucizumab and associated clinical outcomes. Methods We …
real-world experience with idarucizumab and associated clinical outcomes. Methods We …
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis
Introduction Direct thrombin inhibitor, dabigatran and factor Xa inhibitors, apixaban,
edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some …
edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some …